product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
EphB3 Antibody (115) [Alexa Fluor Plus 555]
catalog :
NBP2-90645AFP555
quantity :
0.1 ml
price :
569 USD
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
115
reactivity :
human, mouse
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP2-90645AFP555
SKU :
NBP2-90645AFP555
product name :
EphB3 Antibody (115) [Alexa Fluor Plus 555]
sizes available :
0.1 ml
description :
The EphB3 Antibody (115) [Alexa Fluor Plus 555] from NBP2-90645AFP555 is a 6.7e-05 antibody to . This antibody reacts with mouse.
target :
EphB3
category :
Primary Antibodies
buffer :
50mM Sodium Borate
clonality :
Monoclonal
clone :
115
conjugate :
Alexa Fluor Plus 555
dilution :
ELISA
host :
Rabbit
immunogen :
This antibody was obtained from a rabbit immunized with purified, recombinant Mouse EphB3 (Accession#: NP_034273.1; Met 1-Thr 537).
isotype :
IgG
purity :
Protein A purified
species :
Mouse
specificity :
No cross-reactivity in ELISA with: Human LRPAP1
gene symbol :
EPHB3
applications :
ELISA
extended description :
Recombinant Monoclonal Antibody
USD :
569 USD
product details :
Recombinant Monoclonal Antibody
alt names :
EC 2.7.10, EC 2.7.10.1, EK2, EPH receptor B3, EphB3, EPH-like kinase 2, EPH-like tyrosine kinase-2, ephrin type-B receptor 3, ETK2Hek2, HEK2, human embryo kinase 2, Tyro6, Tyrosine-protein kinase TYRO6
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
questions and comments
